Mortality and major comorbidities in coeliac disease: implications for long-term care Authors: Marco Vincenzo Lenti, Gino Roberto Corazza, Antonio Di Sabatino Published: 2026 Coeliac disease (CD) is a common enteropathy characterised by villous atrophy that is reversible in most cases following withdrawal of gluten from the diet.1 The clinical spectrum of CD ranges from asymptomatic cases to severe malabsorption syndrome. Despite its significant impact, the natural history of CD remains poorly understood, particularly its associated risk of mortality and comorbidities. We read with interest the paper by Ludvigsson and colleagues,2 who investigated mortality, cardiovascular disease, and cancer risk in patients with CD and dermatitis herpetiformis (DH). Specifically, this retrospective study based on the TriNetX database included 204,056 adults with CD and 6896 patients with DH. Compared with matched controls, both groups had higher mortality rates (adjusted hazard ratio [aHR] 1.18 and 1.25 for CD and DH, respectively) and an increased risk of major adverse cardiovascular events (MACE; aHR 1.11 and 1.22 for CD and DH, respectively). In addition, CD was associated with higher rates of haematological malignancies (aHR 1.42), particularly non-Hodgkin lymphoma (aHR 1.51). Patients with DH also had an elevated risk of non-Hodgkin lymphoma (aHR 2.58). This study has several strengths, including a large sample size and the inclusion of both CD and DH, and it substantially advances our understanding of mortality risk and major comorbidities in a non-European population. As the Authors note, the high prevalence of CD suggests that even modest increases in cardiometabolic risk may translate into a substantial population-level disease burden. However, some considerations should be taken into account to better interpret and contextualise these findings. As with other studies relying on administrative data, this work has some limitations that may affect the interpretability. The identification of CD and DH was based on ICD-10 codes, which may have led to some degree of misclassification. Further, serological status and duodenal histology findings were not available. These factors are particularly relevant, as several health outcomes in CD are known to depend on the achievement of mucosal healing.3 For example, persistent villous atrophy has been associated with low bone mineral density, enteropathy-associated T-cell lymphoma, non-Hodgkin lymphoma, and increased mortality.3 In contrast, other manifestations such as infections, overall cancer risk, and ischaemic heart disease, have not been associated with persistent villous atrophy.3 Therefore, prospective studies are needed to determine whether histological healing influences major clinical outcomes. Other key points that should be emphasised are adherence to a gluten-free diet and inadvertent gluten intake. A recent systematic review has shown high and comparable rates of dietary adherence in both Europe and North America4; therefore, it is reasonable to assume that this factor does not substantially affect interpretability across geographical areas. However, food labelling practices and national regulations are considerably more stringent in Europe compared with the USA, where, among gluten-containing cereals, wheat has traditionally been the only cereal required to be disclosed. In a study conducted in the USA assessing gluten contamination in foods labelled as gluten-free, 16/78 (20.5%) products were found to contain ≥20 mg/kg of gluten.5 On 21 January 2026, the FDA issued a press release stating that efforts are underway to improve food labelling for gluten-containing products, including not only wheat, but also rye and barley, which are often not clearly disclosed.6 Indeed, while the study by Ludvigsson and colleagues2 highlights an association between CD/DH and major healthcare outcomes, the underlying mechanisms and preventive strategies remain unclear. With regard to MACE, accumulating evidence points to early vascular involvement, characterised by subclinical atherosclerotic changes, reduced aortic elasticity, and endothelial dysfunction, plausibly mediated by chronic systemic inflammation.7 Therefore, in patients with CD/DH, strict adherence to the latest guidelines on the prevention of cardiovascular-kidney-metabolic syndrome is warranted.8 Regarding mortality, a recent systematic review confirmed an increased risk in CD, while also showing that this excess risk has declined over the last decades.9 In contrast, DH was not associated with increased mortality, consistent with previous evidence.9 The excess mortality reported for DH by Ludvigsson and colleagues2 may be explained by the unexpectedly high prevalence of non-Hodgkin lymphoma, or alternatively by residual confounding factors that were not accounted for. In summary, mortality remains a fascinating yet still insufficiently explored aspect of CD. Interestingly, even in undiagnosed CD, a group that would be expected to represent one of the highest-risk subsets of the CD population, an excess risk of mortality, as well as of comorbidities, has not been consistently demonstrated.10 This apparent paradox underscores the complexity of mortality and comorbidity patterns in CD and highlights the need for further investigation into the factors that truly drive long-term outcomes. Contributors MVL drafted the manuscript; ADS and GRC critically reviewed the manuscript for significant intellectual content; all authors approved the final version for publication. Declaration of interests None to disclose.